Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19356870 | 0.82 | — | — | |
| SCHEMBL101627 | 0.81 | KIF11 (0.32) | KIF11 | |
| SCHEMBL146460 | 0.80 | AR (0.31) | — | |
| SCHEMBL3031821 | 0.79 | — | — | |
| SCHEMBL15319301 | 0.79 | CA2 (0.30) | — | |
| SCHEMBL1958841 | 0.76 | — | — | |
| SCHEMBL17965388 | 0.76 | — | — | |
| SCHEMBL145184 | 0.74 | NOTUM (0.33) | — | |
| SCHEMBL1519797 | 0.74 | AR (0.32) | KIF11 | |
| SCHEMBL454798 | 0.74 | AR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874353-B | Microbiocidal derivatives | 先正达农作物保护股份公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | claimed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | claimed |
| WO-2024073283-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-04 | — | — | WO | claimed |
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-11903936-B2 | Anti-malarial agents | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | claimed |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA, INC. | 2024-02-15 | — | — | US | claimed |
| EP-4077308-B1 | ANTI-MALARIAL AGENTS | UNIV TEXAS (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | claimed |
| US-20030109518-A1 | Substituted 1,4-benzodiazepines and uses thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | claimed |
| WO-2003048156-A1 | SUBSTITUTED 2-PYRROLIDINE-2-YL-1H-INDOLE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | Grünenthal GmbH (DE) | 2003-06-12 | — | — | WO | claimed |
| US-20030105094-A1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2003-06-05 | — | — | US | claimed |
| WO-2003041715-A1 | SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2002076947-A1 | MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| EP-1049670-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2002-07-17 | — | — | EP | claimed |
| EP-1196165-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | claimed |
| WO-2001007022-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | claimed |
| EP-1049670-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037613-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903936-B2 | Anti-malarial agents | PYCR1, DHFR, QDPR | KIF11 2138/4885KDM1A 1230/4885CYP11B1 197/4885 |
| US-20240051960-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | IGLV6-57, TTR, MAP1LC3C | KIF11 2969/4885KDM1A 4460/4885CYP11B1 3372/4885 |
| US-20030105094-A1 | MCH antagonists and their use in the treatment of obesity | MCHR1, MCHR2, MC4R | KIF11 3300/4885KDM1A 250/4885CYP11B1 394/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | KIF11 4642/4885KDM1A 2185/4885CYP11B1 1282/4885 |
| US-20030109518-A1 | Substituted 1,4-benzodiazepines and uses thereof | MDM2, CBR1, ADRM1 | KIF11 2339/4885KDM1A 1431/4885CYP11B1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.